Talzenna

Oncology

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

News

Late-breakers to look out for at ASCO 2026

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

News

Change of heart as NICE backs prostate cancer drug Talzenna

Thousands of men with prostate cancer will be offered a new treatment, Pfizer's Talzenna, after NICE made an about-turn on the drug.

News

Mixed outcomes for pharma in big week for FDA adcomms

There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.

News

NICE backs Pfizer’s Talzenna for advanced breast cancer

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recomm

News

FDA clears J&J's 2-in-1 tablet for prostate cancer

Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Late-breakers to look out for at ASCO 2026

Change of heart as NICE backs prostate cancer drug Talzenna

Mixed outcomes for pharma in big week for FDA adcomms

NICE backs Pfizer’s Talzenna for advanced breast cancer

FDA clears J&J's 2-in-1 tablet for prostate cancer

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Talzenna

Editor's Picks